December 14, 2021Open Access

Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques

YLYan LiState Key Laboratory of Food Science and Technology SSSuzanne E. SchindlerWashington University in St. Louis JBJames G. BollingerWashington University in St. Louis

Key Points

Key points are not available for this paper at this time.

Abstract

This study provides Class II evidence that plasma Aβ42/Aβ40, as measured by a high precision IPMS assay, accurately diagnoses brain amyloidosis in both cognitively unimpaired and impaired research participants.

AI에게 질문

Bookmark

View Full Paper

Cite This Study

Li et al. (Tue,) studied this question.

synapsesocial.com/papers/69dafca00d8d6ef495a3ca4f https://doi.org/https://doi.org/10.1212/wnl.0000000000013211

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1High performance plasma amyloid-β biomarkers for Alzheimer’s disease2018 · 1,705 citations
2Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging2020 · 82 citations
3Detection of β-amyloid positivity in Alzheimer’s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers2021 · 84 citations
4Alzheimer’s Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study2015 · 84 citations
5Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study2021 · 385 citations

AI에게 질문

Bookmark

View Full Paper